Cancer & SURVIVEiT News
FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma
FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients…
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA),…
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with…
FDA granted accelerated approval to tazemetostat for follicular lymphoma
FDA granted accelerated approval to tazemetostat for follicular lymphoma On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for…
A Connection Between Nutrients and Follicular Lymphoma Discovered In New Study
The Spanish National Cancer Research Center recently released a study confirming that the RagC mutation in a follicular lymphoma tumor is “a cause and not a consequence of the disease,…
FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin’s lymphoma
FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin’s lymphoma On November 28, 2018, the Food and Drug Administration approved Truxima (rituximab-abbs, Celltrion Inc.) as the first biosimilar to Rituxan…
FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL
FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL On November 16, 2018, the Food and Drug Administration approved brentuximab vedotin (ADCETRIS, Seattle Genetics Inc.) in combination with…
FDA Announces First Approval for Newly Diagnosed PTCL
FDA Announces First Approval for Newly Diagnosed PTCL NOVEMBER 16, 2018 The FDA approved a new indication for brentuximab vedotin injection (Adcetris, Seattle Genetics). The drug is now approved to…
FDA approves Copiktra for leukemia, lymphoma subtypes
FDA approves Copiktra for leukemia, lymphoma subtypes September 25, 2018 The FDA approved duvelisib for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma…